CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to evaluate the effectiveness of CAN-2409 immunotherapy in patients undergoing active surveillance for localized prostate...
Phase 2
Golden, Colorado, United States and 22 other locations
Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2...
Phase 1
Aurora, Colorado, United States and 50 other locations
to as AAA617. The study also seeks to further characterize (as possible) any other serious adverse reaction(s) in the long-term in adults with prostate...
Phase 4
Aurora, Colorado, United States and 53 other locations
radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stim...
Phase 3
Parker, Colorado, United States and 72 other locations
and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemo ...
Phase 3
Denver, Colorado, United States and 131 other locations
enzalutamide or abiraterone/prednisone alone in asymptomatic or mildly symptomatic subjects with progressive, metastatic castration-resistant prostate...
Phase 1, Phase 2
Denver, Colorado, United States of America and 23 other locations
An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.
Phase 1
Denver, Colorado, United States and 9 other locations
of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate...
Phase 2
Lone Tree, Colorado, United States and 25 other locations
plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednison...
Phase 2, Phase 3
Lone Tree, Colorado, United States and 112 other locations
therapy in participants with metastatic castration resistant prostate cancer (mCRPC). There will be ten cohorts in this study: Coho...
Phase 1, Phase 2
Aurora, Colorado, United States and 27 other locations
Clinical trials
Research sites
Resources
Legal